Suppr超能文献

遗传性出血性疾病患者中丙型肝炎感染的长期随访。

Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.

机构信息

Van Creveldkliniek, Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.

Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Sheffield, United Kingdom.

出版信息

J Hepatol. 2014 Jan;60(1):39-45. doi: 10.1016/j.jhep.2013.08.010. Epub 2013 Aug 23.

Abstract

BACKGROUND & AIMS: Patients with inherited bleeding disorders are an interesting group to study the long-term course of chronic hepatitis C virus (HCV) infection, because of their uniform mode of infection and reliable follow-up. Our aim was to assess the long-term occurrence of adverse liver-related events in these patients.

METHODS

The occurrence and determinants of end-stage liver disease (ESLD) were assessed using retrospective data of 863 HCV infected patients with inherited bleeding disorders from the Netherlands and the UK.

RESULTS

Median follow-up since HCV infection was 31 years, while 30% of patients had >35 follow-up years. Nineteen percent of patients spontaneously cleared the virus and 81% developed chronic HCV infection. Of the 700 patients with chronic HCV, 90 (13%) developed ESLD. Hepatocellular carcinoma (HCC) was diagnosed in 3% of patients with chronic HCV, 41% of which occurred in the last six years. Determinants of ESLD development were age at infection (hazard ratio (HR) 1.09 per year increase), HIV co-infection (HR 10.85), history of alcohol abuse (HR 4.34) and successful antiviral treatment (HR 0.14). Of the 487 patients who were still alive at the end of follow-up, 49% did not undergo optimal conventional antiviral treatment.

CONCLUSIONS

After over 30 years of HCV infection, ESLD occurred in a significant proportion of patients with inherited bleeding disorders. HCC appears to be an increasing problem. There is a significant potential for both conventional and new antiviral treatment regimens to try and limit ESLD occurrence in the future.

摘要

背景与目的

由于遗传性出血性疾病患者的感染方式一致且可进行可靠的随访,因此他们是研究慢性丙型肝炎病毒(HCV)感染长期病程的一个有趣群体。我们的目的是评估这些患者发生不良肝脏相关事件的长期情况。

方法

使用来自荷兰和英国的 863 名遗传性出血性疾病合并 HCV 感染患者的回顾性数据,评估终末期肝病(ESLD)的发生和决定因素。

结果

自 HCV 感染以来的中位随访时间为 31 年,而 30%的患者随访时间超过 35 年。19%的患者自发清除了病毒,81%的患者发展为慢性 HCV 感染。在 700 名患有慢性 HCV 的患者中,90 名(13%)发生了 ESLD。慢性 HCV 患者中有 3%被诊断出患有肝细胞癌(HCC),其中 41%发生在过去六年中。ESLD 发展的决定因素包括感染时的年龄(每年增加的风险比(HR)为 1.09)、HIV 合并感染(HR 10.85)、酒精滥用史(HR 4.34)和成功的抗病毒治疗(HR 0.14)。在随访结束时仍存活的 487 名患者中,49%未接受最佳常规抗病毒治疗。

结论

在 HCV 感染 30 多年后,遗传性出血性疾病患者中出现 ESLD 的比例显著。HCC 似乎是一个日益严重的问题。未来,无论是传统还是新的抗病毒治疗方案,都有很大的潜力尝试限制 ESLD 的发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验